CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
Authors
N. Abdollahi
A. Abedini
+17 more
N. Anjidani
M. Darban
F. Dastan
R. Ghasemian
H. Hosseini
S.A. Javad-Mousavi
S. Kalantari
R. Khodashahi
F. Khorvash
R. Malekzadeh
B. Mohsenpour
A. Rezaei Hosseinabadi
M.R. Salehi
E. Sharifipour
P. Tabarsi
M. Valizadeh
S. Yousefian
Publication date
1 January 2020
Publisher
Abstract
Potential therapeutic approaches in coronavirus disease 2019 (COVID-19) comprise antiviral and immunomodulatory agents; however, no immunomodulator drug has been approved. This multicenter, prospective, open-label, uncontrolled study aimed to assess the use of subcutaneous tocilizumab in adult patients with severe and critical COVID-19. Tocilizumab was added to the standard care of therapy at a dose of 324 mg (<100 kg bodyweight) or 486 mg (�100 kg bodyweight). The study endpoints were all-cause mortality rate, changes in oxygen-support level, oxygen saturation, body temperature, respiratory rate, and laboratory variables during the study, and drug safety. Of 126 patients enrolled, 86 had severe and 40 had critical disease. Most patients were male (63.49) and aged below 65 (78.57). By day 14 of the study, 4.65 (4/86) of severe patients and 50.00 (20/40) of critical patients died. By the end, 6.98 (6/86) of severe patients and 60.00 (24/40) of critical patients died. Outcomes concerning three additional endpoints (oral temperature, oxygen saturation, and respiratory rate) were significantly improved as early as three days after tocilizumab administration in both groups of subjects, more considerably in severe patients. Significant improvement in the required level of oxygenation was reported in severe patients seven days after tocilizumab administration. No tocilizumab-related serious adverse event occurred in this study. Subcutaneous tocilizumab might improve some clinical parameters and reduce the risk of death in COVID-19 patients, particularly if used in the early stages of respiratory failure. © 202
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
eprints Iran University of Medical Sciences
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.iums.ac.ir:33665
Last time updated on 03/06/2021
Golestan University of Medical Sciences Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.goums.ac.ir:10828
Last time updated on 21/11/2020